Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

NCT02396212 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Juvenile Idiopathic Arthritis

Interventions

BIOLOGICAL: Canakinumab

Sponsor

Novartis Pharmaceuticals